Form 8-K - Current report:
SEC Accession No. 0001628280-25-002466
Filing Date
2025-01-24
Accepted
2025-01-24 16:00:52
Documents
13
Period of Report
2025-01-23
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20250123.htm   iXBRL 8-K 30950
  Complete submission text file 0001628280-25-002466.txt   158096

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20250123.xsd EX-101.SCH 1788
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20250123_lab.xml EX-101.LAB 22543
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20250123_pre.xml EX-101.PRE 13047
15 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20250123_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 25554097
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)